Investing.com investing.com 30 Dec, 2020 23:00 am

UK nod for AstraZeneca vaccine raises more questions By Reuters

UK nod for AstraZeneca vaccine raises more questions By Reuters
No half measures and mind the gap: UK nod for AstraZeneca vaccine raises more questions

"The low dose/standard dose regimen, although it has been quoted to have an efficacy of 90%, this is confounded by the fact that the interval between the first and second dose was quite long," Pirmohamed told a news conference.The UK's COVID-19 vaccine chair, Wei Shen Lim, said a single dose of Oxford/AstraZeneca's vaccine was around 70% effective from 21 days until a second dose was given.Britain’s Medicines and Healthcare Products Regulatory Agency (MHRA) recommended an interval of between 4-12 weeks between doses of the AstraZeneca/Oxford vaccine and also updated its guidance for a second dose of the Pfizer-BioNTech shot saying it could be administered within 12 weeks, rather than the 21 days originally recommended.Pfizer sounded cautious on the prospect of shifting the schedule of its second dose, noting it had not been evaluated on different dosing schedules.

Jeremy Farrar, director of health research foundation Wellcome, said a new trial might be needed to give clearer data on the best timing of a second dose."This would be best achieved by a randomised trial on the timing of the second dose.

Read full story at investing.com